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Summary
BACKGROUND: Surgical aortic valve replacement
(SAVR) is the treatment of choice in severe symptomatic
aortic valve disease. New techniques and prostheses
have been recently developed to facilitate the procedure
and reduce aortic cross-clamp time (AOx). The aim of this
study was to analyse the different procedural steps in or-
der to identify the most time-consuming part during aor-
tic clamping time and to compare impact of experience on
procedural aspects.
METHODS: AOx during SAVR was divided into five con-
secutive steps. Duration of each step was measured. The
first procedural step started with clamping of the aorta and
ended with the beginning of the second step starting with
the resection of the native aortic valve. The third step start-
ed with placement of the first valve anchoring suture, the
fourth step started with tying of the first suture and the fifth
and final step started after the cut of the last suture and
ended with removal of the aortic clamp. Surgeons were di-
vided into two groups based on their experience, which in
our analysis was defined as a total SAVR experience of
more than 100 procedures.
RESULTS: From March 2013 to August 2015 57 noncon-
secutive patients (33% female; age, median 71.0 years,
interquartile range 65.0–76.0) undergoing isolated SAVR
for severe aortic valve stenosis in our institution were in-
cluded in this process analysis. Two different prostheses
were implanted. Forty-eight (84%) patients received a tis-
sue valve (Perimount Magna Ease, Edwards Lifesciences,
Irvine, USA) and 9 (16%) patients received a mechanical
prosthesis (Medtronic AP 360, St-Paul, MN, USA). The
mean estimated risk of mortality was 1.1% (0.7–1.6) ac-
cording to the logistic EUROScore II. Overall duration of
AOx was 50.5 ± 13.8 min, with 32.3% (16.4 ± 5.9 min)
accounting for placing the sutures into the native annulus
and the prosthetic sewing ring and 18.5% (9.2 ± 3.0min)
accounting for tying and cutting the sutures. Surgeons with
more experience performed 35 operations (61.4%) and
needed an average of 44.1 ± 11.5 min versus 60.6 ± 11.0
min (p <0.001) for less experienced surgeons. Surgeons
with more experience needed 14.0 ± 5.0 min for the sutur-
ing step and 8.4 ± 2.8 min for tying the sutures compared
with 20.2 ± 5.2 min and 10.5 ± 3.0 min, respectively, for the
less experienced surgeons with (p <0.001 and p = 0.010).
CONCLUSION: Placing and tying sutures in the prosthe-
ses accounts for over half (50.8%) of AOx during isolated
SAVR. Experienced surgeons have significantly reduced
AOx. This shortening is equally distributed between all five
procedural steps.
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Introduction
Aortic stenosis is the most common acquired valvular heart
disease in Europe and North America. The prevalence of
aortic stenosis in patients at the age 65 years or above
varies between 2 and 7% [1–3]. Aortic stenosis occurs
from age-related degenerative calcification or, rarely, from
previous rheumatic fever in both tricuspid and bicuspid
valves.
According to the recommendations of the American Col-
lege of Cardiology and the American Heart Association
guidelines, the treatment of choice for severe aortic valve
stenosis is either surgical aortic valve replacement or, in se-
lected (mainly older and high-risk) patients, transcatheter
aortic valve implantation [4]. Surgical aortic valve replace-
ment (SAVR) through a median sternotomy has been the
treatment of choice for symptomatic, severe aortic stenosis
over decades. Continuous improvement in surgical tech-
niques and new technologies aiming at facilitating and re-
ducing operative times allow increased performance for
all patients groups, including elderly patients and patients
with more comorbidities.
The literature does not provide detailed process analyses of
conventional SAVR, which would add to the understand-
ing of the most technically demanding and time-consum-
ing parts of the operation.
Thus, we aimed to systematically analyse the different
procedural steps of aortic valve replacement by using a
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process analysis in order to identify the most time-consum-
ing parts during SAVR according operator experience.
New devices and techniques
Ministernotomy
Less invasive strategies, such as minimal invasive surgical
techniques (fig. 1), have been developed and introduced in-
to clinical routine with outcomes equivalent to convention-
al approaches [5–10]. However, minimal invasive surgical
techniques are technically more demanding, with high in-
teroperator variability in procedural duration and clinical
outcomes. The reduction of surgical exposure and working
space can lead to technical difficulties in accessing the
aortic valve, thereby resulting in an increase in cardiopul-
monary bypass time (CPB) and aortic cross-clamp time
(AOx) [5, 6], which in turn might be associated with worse
postoperative outcomes [11–13].
Sutureless valve prosthesis
Sutureless valve prostheses were designed to combine the
advantages of transcatheter technology and surgical valve
replacement. The aim of sutureless valves is to simplify the
procedure and to reduce intervention time.
In the last few years, the surgical experiences with three
sutureless devices have been reported: the 3f Enable valve
(Medtronic, Minneapolis, MN), the Perceval S valve
(Sorin Group, Saluggia, Italy) and the Intuity Valve System
(Edwards Lifesciences Corporation, Irvine, CA).
Cor-Knot Device
Most recently the Cor-Knot device (LSI Solutions, Victor,
NY, USA), a tying and cutting device, which was designed
to fasten and optimise knotting especially in a minimally
invasive setting, was introduced into clinical practice for
valve surgery (fig. 2).
Methods
Patient selection
For the purpose of this process analysis, baseline, proce-
dural and outcome data of 57 nonconsecutive patients un-
dergoing isolated SAVR for severe aortic valve stenosis
through complete sternotomy were prospectively collected
between March 2013 and August 2015. Patients with pre-
vious cardiac surgery, the need for concomitant coronary
artery bypass grafting, a minimally invasive approach or
other cardiac procedures in addition to SAVR were ex-
cluded from this analysis. All patients provided written in-
formed consent to be included in the registry with prospec-
tive follow-up assessment.
Surgeons’ experience
The experience of a surgeon was graded according to the
total SAVR experience. Surgeons who had performed more
than 100 SAVR procedures through median sternotomy
were considered “more experienced”, whereas surgeons
with a total experience of less than 100 SAVR procedures
were considered “less experienced”, and were analysed
separately. A total of 10 cardiovascular surgeons per-
formed SAVR on the 57 patients. Five surgeons were con-
sidered more experienced.
Surgical technique and time measurement
In all patients, SAVR was performed in a standardised
fashion through median sternotomy with mild hypother-
mia. After central cannulation and initiation of cardiopul-
monary bypass circulation, the aorta was cross-clamped
and cardioplegia was induced in an antegrade fashion. Ac-
cording to the institutional practice, a standard technique
was used for the implantation of the prosthetic aortic valve.
The type of aortic valve prosthesis (biological or mechani-
cal prosthesis) was left to the discretion of the surgeon and
the patient, and followed the general recommendations of
Figure 1: Demonstration of the two most common approaches through ministernotomy (image courtesy of Edwards Lifesciences Corporation).
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the latest version of the European Society of Cardiology
guidelines for the treatment of valvular heart disease [14].
After cross-clamping the study specific time measurement
started using five consecutive procedural steps:
Step 1: Exposure started immediately after aortic cross-
clamping and included the induction of cardioplegia and
full exposure of the aortic valve.
Step 2: Resection was initiated with the start of resection
of the calcified aortic valve, including the decalcification
of the aortic annulus as well as the annulus measurement
with the prosthesis-specific sizer in order to determine the
size of the prosthesis.
Step 3: Suturing started with the first suture to be placed
into the native aortic annulus.
Step 4: Tying started with the first knot of the sutures of the
aortic valve prosthesis and lasted until cutting of the last
suture.
Step 5: Declamping was defined as the time window after
cutting the last suture until removal of the aortic cross
clamp.
All time windows were measured by one dedicated person
(M.N.) using a conventional stopwatch.
Statistical analysis
Statistical analysis was performed using Stata 12 (College
Station, Texas, USA). Data are presented as mean and stan-
dard deviation, median with interquartile range (IQR) and
number with percent, according to the type and distribution
of the data. Differences between the experienced and less
Figure 2: Intraoperative application of the Cor-Knot Device for aortic valve fixation (images courtesy of LSI SOLUTIONS®).
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experienced surgeons’ operations were assessed with un-
paired student t-tests, median tests or chi-squared tests, as
appropriate. All p-values are two sided and p-values <0.05
were considered statistically significant.
Results
Between March 2013 and August 2015, 57 nonconsecutive
patients with symptomatic, severe aortic stenosis undergo-
ing isolated SAVR were selectively included in this study.
Baseline clinical characteristics are presented in table 1.
Patients were predominantly male (67%), with a median
age of 71.0 years (IQR 65.0–76.0 years). All patients were
symptomatic (23% New York Heart Association functional
class III and IV) and presented with a transvalvular mean
pressure gradient of 45.2 ± 16.7 mm Hg, a calculated aortic
valve area of 0.8 ± 0.2 cm2 and an ejection fraction of
65.0% (57.0–65.0%). The estimated risk of mortality
amounted to 1.1% (0.7–1.6%) according to the logistic
EUROScore II. Overall, AOx was 50.5 ± 13.8 min. The
duration of each step assessed during AOx is depicted in
fig. 3. The exposure of the aortic valve (duration 5.2 ±
2.8 min, ≈10.5% of AOx) was followed by resection of the
degenerated native cusps (valve resection, 8.2 ± 4.4 min,
≈16.0% of AOx). Placement of the sutures accounted for
32.3% of AOx (16.4 ± 5.9 min) and tying the sutures in the
fourth step took 9.2 ± 3.0 min (≈18.5% of AOx). The pe-
riod from cutting the last suture until declamping the aorta
lasted 11.4 ± 3.9 min (≈22.8% of AOx).
Surgeons with more experience performed 35 operations
(61.4%) and needed an average of 44.1 ± 11.5 min versus
60.6 ± 11.0 min (p <0.001) for less experienced surgeons.
Procedural characteristics are presented in table 2. Sur-
geons with more experience needed 14.0 ± 5.0 min for the
suturing step and 8.4 ± 2.8 min for tying the sutures; less
experienced surgeons needed 20.2 ± 5.2 min and 10.5 ±
3.0 min, respectively, (p <0.001 and p = 0.010 in compar-
ison with more experienced surgeons). The distribution of
each step is shown in fig. 4.
The majority of patients (n = 48, 84%) received a Per-
imount Magna Ease tissue prosthesis (Edwards Life-
sciences, Irvine, USA) and 9 patients (16%) received a
Medtronic AP 360 medical mechanical prosthesis
(Medtronic, Inc., Minneapolis, USA). In total a mean of
15.0 ± 2.0 sutures were used for aortic valve fixation. In
six patients, three of each group, data were missing. Sur-
geons with more experience used a mean of 14.4 ± 1.8 su-
tures versus 15.9 ± 2.0 sutures (p = 0.005) used by the less
experienced group. Table 3 shows the various sizes of the
prosthesis and the amount of sutures used.
Overall in-hospital mortality was 0%. Follow up echocar-
diographic assessment was complete in 25 patients
(43.9%), of whom 16 were operated on by the more ex-
perienced group and 9 by the less experienced group, and
showed a mean gradient of 10.0 mm Hg
(7.0–14.0 mm Hg). Postoperative data for experienced sur-
geons showed a mean gradient of 9.5 mm Hg (6.5–14.0)
Figure 3: Distribution of the five steps of aortic cross-clamp time.
Table 1: Baseline clinical characteristics.
All patientsn = 57 Less experienced surgeonsn
= 22
More experienced surgeonsn
= 35
p-value
Age (years) 71.0 (65.0–76.0) 69.5 (65.0–76.0) 72.0 (63.0–76.0) 0.166
Female gender, n (%) 19 (33) 8 (36) 11 (31) 0.700
Body mass index (kg/m2) 26.2 (24.1–30.7) 29.4 (25.2–31.9) 25.8 (24.0–28.8) 0.093
Cardiac risk factors
Diabetes mellitus, n (%) 11 (19) 6 (27) 5 (14) 0.227
Dyslipidaemia, n (%) 36 (63) 14 (64) 22 (63) 0.953
Hypertension, n (%) 32 (56) 13 (59) 19 (54) 0.722
Current smoker, n(%) 7 (12) 2 (9) 5 (14)
Past medical history
Coronary artery disease, n (%) 7 (12) 0 (0) 7 (20) 0.025
Renal failure (GFR<60ml/min/1.73 m2), n (%) 10 (18) 5 (23) 5 (14) 0.415
Previous stroke, n (%) 2 (4) 0 (0) 2 (6) 0.254
Peripheral vascular disease, n (%) 3 (5) 1 (5) 2 (6) 0.847
Clinical features
Left ventricular ejection fraction (%) 65.0 (57.0–65.0) 65.0 (55.0–70.0) 63.5 (58.5–65.0) 0.153
Aortic valve area (cm2) 0.8 ± 0.2 0.8 ± 0.1 0.8 ± 0.2 0.483
Mean transaortic gradient (mm Hg) 45.2 ± 16.7 46.7 ± 10.5 44.3 ± 19.5 0.639
Symptoms (New York Heart Association functional class)
I + II, n (%) 42 (73) 15 (69) 27 (77)
III + IV, n (%) 13 (23) 5 (23) 8 (23)
Risk assessment
EuroScore II (%) 1.1 (0.7–1.6) 0.9 (0.7–1.3) 1.2 (0.7–1.7) 0.295
GFR = glomerular filtration rate Data are presented as mean ± standard deviation, median (interquartile range), or n (%) as appropriate
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versus 10.0 mm Hg (8.0–17.0) (p = 0.70) for the less expe-
rienced group. Echocardiographic suspicion of trivial par-
avalvular leakage was found in one patient in the less ex-
perienced group.
Discussion
This institutional process analysis investigating the differ-
ent steps during conventional SAVR was able to confirm
our initial expectation that the time period for prosthetic
valve fixation, including placing and tying the sutures, is
the most time-consuming part of the procedure at 16.4 min
(32.3%) and 9.2 min (18.5%), respectively. Both account
for over 50% of the cross-clamp time.
Surgeon's experience
The importance of the surgeon’s experience is a well-
known and significant factor that reduces AOx and may
improve patient outcomes. During this process analysis,
the experience of a surgeon was the most remarkable factor
for the reduction of AOx. Compared with more experi-
enced surgeons, who in our study were defined as a total
aortic valve replacement experience of more than 100 pro-
cedures, surgeons with only limited experience (younger
senior residents or surgical assistants still in the teaching
programme) in SAVR had significantly longer AOx (60.6
± 11.0 vs 44.1 ± 11.5 min, p <0.001). In comparison with
experienced surgeons, they showed an equal distribution of
the AOx between the different steps.
Interestingly, when the AOx of experienced surgeons in
our study is compared with the AOx reported in the litera-
ture for procedures using sutureless aortic valve prosthesis,
durations are similar despite use of the sutureless valve.
AOx has been reported to be 39 ± 15 min for implanting
the 3f Enable valve [15], 41.1 ± 10.6 min for the Edwards
Intuity Valve System [13] and 40 ± 13.8 min for the Perce-
val S aortic bioprosthesis [16]; in our study, AOx during
SAVR was 44.1 ± 11.5 min but went as low as 25 min, with
a sutured aortic valve prosthesis and without the help of
automated devices.
Another factor contributing to a longer AOx in surgeons
with a lesser degree of experience might be linked to the
number of sutures used for fixation of the aortic valve
prosthesis. These numbers have not been reported in the
literature so far. We were able to show a significantly lower
Table 2: Procedural characteristics and outcomes.
All patients
Less experienced surgeonsn =
22
More experienced surgeonsn = 35
p-value Decrease* (%)
Procedure
Aortic cross-clamp time (min) 60.6 ± 11.0 (100) 44.1 ± 11.5 (100) <0.001
Exposure, min (% AOx) 6.6 ± 3.7 (10.9) 4.4 ± 1.5 (10.2) 0.002 33
Resection, min (% AOx) 9.9 ± 4.5 (16.4) 7.1 ± 4.1 (15.8) 0.021 28
Suturing, min (% AOx) 20.2 ± 5.2 (33.3) 14.0 ± 5.0 (31.6) <0.001 31
Tying, min (% AOx) 10.5 ± 3.0 (17.2) 8.4 ± 2.8 (19.2) 0.010 20
Declamping, min (% AOx) 13.4 ± 3.0 (22.1) 10.2 ± 4.0 (23.3) 0.002 24
Prothesis
Perimount Magna Ease tissue prosthesis, n (%) 18 (81.8) 30 (85.7)
Medtronic ATS medical mechanical prosthesis, n (%) 4 (18.2) 5 (14.3)
Prosthesis size, mm 23.7 ± 2.1 23.4 ± 2.2 0.55
Sutures, n 15.9 ± 2.0 14.4 ± 1.8 0.005
Postoperative Data
Mean transaortic gradient, mm Hg 10.0 (8.0–17.0) 9.5 (6.5–14.0) 0.7
Paravalvular leak, n (%) 1 (4.5) –
In-hospital mortality, n (%) 0 (0) 0 (0)
AOx = aortic cross-clamp time Data are presented as mean ± standard deviation, median (interquartile range), or n (%) as appropriate. * The average reduction in time that more
experienced surgeons need as compared with less experienced surgeons.
Table 3: Type of aortic valve prosthesis and number of sutures required.
All Patients
Less experienced surgeons More experienced surgeons
n (%) Sutures, n n (%) Sutures, n
Edwards Lifesciences, sizes
19 mm 0 (0) 1 (3.3) 12.0 ± 0.0
21 mm 4 (22.2) 14.3 ± 0.6 5 (16.7) 12.3 ± 0.5
23 mm 6 (33.3) 16.6 ± 3.6 14 (46.7) 14.5 ± 1.1
25 mm 5 (27.8) 16.2 ± 0.8 7 (23.3) 15.4 ± 1.9
27 mm 3 (16.7) 16.5 ± 0.7 2 (6.7) 16.0 ± 0.0
29 mm 0 (0) 1 (3.3)
Medtronic, sizes
18 mm 0 (0) 1 (20) 11 ± 0.0
20 mm 1 (25) 15 ± 0.0 1 (20) 13 ± 0.0
22 mm 0 (0) 1 (20) 13 ± 0.0
24 mm 2 (50) 15.5 ± 0.7 2 (40) 15.5 ± 0.7
26 mm 1 (25) 17.0 ± 0.0 1 (20) 17.0 ± 0.0
Data are presented as n (%) or mean ± standard deviation.
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number of sutures used for valve fixation by more experi-
enced surgeons when compared with less experienced sur-
geons (14.4 ± 1.8 vs 15.9 ± 2.0 sutures, p = 0.005), with
similar postoperative echocardiographic results in both
groups: more experienced surgeons, mean gradient
9.5 mm Hg (6.5–14.0) vs less-experienced surgeons, mean
gradient 10.0 mm Hg (8.0–17.0), p = 0.70.
Ministernotomy
In general, the literature reports longer CPB and AOx in
SAVR through ministernotomy [5, 6, 9], although isolated
studies showed no difference in CPB or AOx, but a longer
total operating time [8]. Interestingly, one study even re-
ported a shortening of CPB and AOx with the minimal-in-
vasive techniques [7]. These different results might relate
to the different sizes of the study populations or to the use
of different statistical methods. Although these studies re-
ported no difference in short- or long-term mortality, they
did show a reduction of mechanical ventilation time, less
blood loss and shorter intensive care unit and hospital stay
in the minimal invasive patient population [5–9].
Sutureless valve prosthesis
The Edwards Intuity valve system was investigated in a
consecutive patient population of 152 patients with symp-
tomatic, severe aortic stenosis. In this study, the direct su-
tureless fixation of the aortic bioprosthesis in the aortic an-
nulus was able to reduce AOx by 23.5% [16]. Moreover,
the surgical implantation of the Perceval S aortic biopros-
thesis was able to reduce AOx by 39.4% [17] compared
with standard SAVR by conventional techniques. Usage of
the 3f Enable valve was able to reduce AOx by 38.5% [18].
At present there is only a single 5-year follow-up study of
the 3f Enable prosthesis, showing very satisfactory clinical
outcome with a reoperation rate of only 1.3%, occurrence
Figure 4: Comparison between less and more experienced sur-
geons in distribution of the five steps of aortic cross-clamp time.
of major paravalvular leak in only 0.8% and valve-related
death in 1.6% of 141 patients. Haemodynamic parameters
such as peak and mean systolic gradient were stable dur-
ing 5 years of follow-up [19]. However, in some studies,
sutureless valves have shown higher short-term complica-
tion rates compared with conventional SAVR [20, 21]. A
further study noted that patients receiving sutureless valves
had a higher rate of postoperative permanent pacemaker
implantation [19].
Cor-Knot device
At present, only studies on mitral valve annuloplasty with
use of the automated knotting/cutting device in minimal-
invasive operation have been published. These studies
compared the use of the Cor-Knot devices with manually
tied knots and a traditional knot pusher. Some studies re-
port a significant reduction of CPB and AOx, as well as of
the total operation time. They have shown equal morbidi-
ty and mortality [22, 23]. No studies report a comparison
between Cor-Knot device and manually tied knots without
the use of a knot pusher. In an ex-vivo setting, however, one
study was able to show a significant time reduction com-
pared with manual tying of sutures (12.4 vs 71.1 seconds
per knot, p = 0.001) [21].
Limitations
The following limitations need to be acknowledged: first,
the study population was based on the experience of a sin-
gle, tertiary care and teaching centre and the results may
not be applicable to other centres with different procedur-
al experience and patient selection; second, the process
analysis included only a small number of patients and a
larger study is required for the confirmation of our results;
and finally, although patient and procedural data were col-
lected prospectively, a certain selection bias might be pre-
sent in the results of this study and cannot be excluded.
Conclusion
During isolated surgical aortic valve replacement for aortic
valve stenosis, placing and tying the sutures accounts for
50.8% of the total aortic cross clamp time. Surgical expe-
rience impacts the five procedural steps equally. If a sig-
nificant reduction in cross-clamp time might be beneficial
for more complex patients (combined procedures, redo,
high risk), these two steps may be shortened by automated
processes.
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